Literature DB >> 9478282

Quantitation and gompertzian analysis of tumor growth.

K Rygaard1, M Spang-Thomsen.   

Abstract

Human tumor xenografts in immune-deficient animals are used to establish tumor growth curves and for studying the effect of experimental therapy on tumor growth. In this review we describe a method for making serial measurements of tumor size in the nude mouse model as well as methods used to transform the experimental data into useful growth curves. A transformed Gompertz function is used as the basis for calculating relevant parameters pertaining to tumor growth and response to therapy. The calculations are facilitated by use of a computer program which performs the necessary calculations and presents the growth data in graphic form.

Entities:  

Mesh:

Year:  1997        PMID: 9478282     DOI: 10.1023/a:1005906900231

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

1.  Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure.

Authors:  Minna W B Olsen; Carsten D Ley; Nanna Junker; Anker J Hansen; Eva L Lund; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Imaging transgene activity in vivo.

Authors:  Terence P F Gade; Jason A Koutcher; William M Spees; Bradley J Beattie; Vladimir Ponomarev; Michael Doubrovin; Ian M Buchanan; Tatiana Beresten; Kristen L Zakian; H Carl Le; William P Tong; Philipp Mayer-Kuckuk; Ronald G Blasberg; Juri G Gelovani
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

3.  Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography.

Authors:  Sabrina Doblas; Ting He; Debbie Saunders; Jamie Pearson; Jessica Hoyle; Nataliya Smith; Megan Lerner; Rheal A Towner
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

4.  Effect of censoring due to progressive disease on tumor size kinetic parameter estimates.

Authors:  Peter L Bonate; Ben Suttle
Journal:  AAPS J       Date:  2013-04-20       Impact factor: 4.009

Review 5.  Three endpoints of in vivo tumour radiobiology and their statistical estimation.

Authors:  Eugene Demidenko
Journal:  Int J Radiat Biol       Date:  2010-02       Impact factor: 2.694

6.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Alpha-lactosylceramide as a novel "sugar-capped" CD1d ligand for natural killer T cells: biased cytokine profile and therapeutic activities.

Authors:  Wenpeng Zhang; Xincheng Zheng; Chengfeng Xia; Ramu Sridhar Perali; Qingjia Yao; Yang Liu; Pan Zheng; Peng George Wang
Journal:  Chembiochem       Date:  2008-06-16       Impact factor: 3.164

8.  Morphologic changes of mammary carcinomas in mice over time as monitored by flat-panel detector volume computed tomography.

Authors:  Jeannine Missbach-Guentner; Christian Dullin; Sarah Kimmina; Marta Zientkowska; Melanie Domeyer-Missbach; Cordula Malz; Eckhardt Grabbe; Walter Stühmer; Frauke Alves
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

9.  Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.

Authors:  Terence P F Gade; Ian M Buchanan; Matthew W Motley; Yousef Mazaheri; William M Spees; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

Authors:  Donita C Brady; Matthew S Crowe; Danielle N Greenberg; Christopher M Counter
Journal:  Cancer Res       Date:  2017-10-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.